Presentations
David Kalergis, Chief Executive Officer, Diffusion Pharmaceuticals LLC
Case Study: Global Partnering Challenges: A Small Biotech’s Perspective
Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America
Case Study: The $8.8 Billion Acquisition of Millennium Pharmaceuticals By Japan’s Takeda
Anna Protopapas, Senior Vice President of Corporate Development, Millennium Pharmaceuticals
Case Study: The $8.8 Billion Acquisition of Millennium Pharmaceuticals By Japan’s Takeda
Reid Leonard, Vice President, External Licensing and Business Development, Merck
Case Study: Merck’s Partnerships In India
Stephanie Hsieh, Senior Director, Intellectual Property and Legal Affairs, Impax Laboratories
Case Study: Discussing The Competitive Advantages Of Bringing Generic Drugs Into The Branded Space
David Paterson PhD, Vice President, Business Development, Impax Pharmaceuticals, Inc
Case Study: Discussing The Competitive Advantages Of Bringing Generic Drugs Into The Branded Space
Iain Dukes, President and CEO, Essentialis
Case Study: Planning For The Big Deal: Options Analysis Ahead Of Critical Data
Pavan Handa, Vice President, Business Development and Alliance Management, Noven Pharmaceuticals, Inc.
Building a Profitable Product Portfolio Utilizing Innovative Drug Delivery Technologies
Jeffrey Totten, Vice President, Dean & Company
Chairperson’s Morning Opening Remarks
Jeffrey Totten, Vice President, Dean & Company
Chairperson’s Afternoon Opening Remarks
Lily Zou, Director, Business Development, ArQule, Inc.
Therapeutic Area Partnering Primers-Oncology
Iain Dukes, President and CEO, Essentialis
Therapeutic Area Partnering Primers- Cardiovascular
Vidal de la Cruz, Vice President, Business Development, Cytokine PharmaSciences, Inc.
Therapeutic Area Partnering Primers-Auto-Immune
Ira Weisberg, Vice President, Business Development, Lifecycle Pharma
Case Study: Successfully Negotiating Structured Royalty Agreements
Matt Reber, Vice President, Cowen Healthcare Royalty Partners
Case Study: Successfully Negotiating Structured Royalty Agreements
John M. Hession, Partner In Charge, Boston Offices, Cooley Godward Kronish LLP
Panel Discussion: Creative Exit Strategies For Biotech Companies
Matt Meyer, Vice President Business Development and Licensing, Cerimon
Case Study: Understanding The Unique Collaboration Between Large Pharma (Novartis) And Small Pharma (Cerimon)
Arne Wörn PhD, Head Alliance Management, Immunology & Infectious Diseases Business Franchise, Global Business Development & Licensing, Novartis Pharma
Case Study: Understanding The Unique Collaboration Between Large Pharma (Novartis) And Small Pharma (Cerimon)
Thanos Maroglou, Vice President, Business Development, Chimerix Inc.
Panel Discussion: Creative Exit Strategies For Biotech Companies
Stephen Potter, Senior Vice President of Corporate Business Development, Genzyme
Panel Discussion: Creative Exit Strategies For Biotech Companies
Andrew Eibling, Manager, Alliance Management, Eli Lilly & Co.
Opening Panel Discussion: Proactive Approaches In Managing The Business Within Alliances
Jonathan Montagu, Director, Business Development, Concert Pharmaceuticals
Closing Panel Discussion: Continuing To Fund Your Portfolio In A Weak Financial Market
David Wurtman, Vice President, Business Development, NexBio
Therapeutic Area Partnering Primers-Infectious Disease
Sanj Singh, CEO, Ade Therapeutics
Global Partnering Roundtable Discussions -Canada, Canadian Research and Development Content Programs
Sanj Singh, CEO, Ade Therapeutics
Global Partnering Roundtable Discussions -Canada
Dr. Seth Rudnick, Venture Partner, Canaan Partners
Panel Discussion: Creative Exit Strategies For Biotech Companies
Beth Fordham-Meier, Senior Director, Business and Commercial Development, Targacept, Inc.
Opening Panel Discussion: Adding Value To A Deal – Utilizing Non Cash Assets Or Creatively Using Cash To Enhance Partnerships
Len Smith, Senior Intellectual Property Counsel, Novo Nordisk
Closing Discussion: Global Patent & Regulatory Strategies
Beth Fordham-Meier, Senior Director, Business and Commercial Development, Targacept
Therapeutic Area Partnering Primers-Central Nervous System